

Datasheet: MCA2200B

Description:	MOUSE ANTI C-MYC:Biotin
Specificity:	C-MYC
Format:	Biotin
Product Type:	Monoclonal Antibody
Clone:	9E10
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

RRID AB_323950

Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Immunohistology - Frozen	▪			
Immunohistology - Paraffin	▪			
ELISA	▪			1/20 - 1/50
Immunoprecipitation			▪	
Western Blotting (1)	▪			

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems using appropriate negative/positive controls.

(1)**9E10 recognizes c-myc under non-reducing conditions**

Target Species Human

Product Form Purified IgG conjugated to Biotin - liquid

Preparation Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant

Buffer Solution Phosphate buffered saline

Preservative 0.09% Sodium Azide
Stabilisers 1% Bovine Serum Albumin

Approx. Protein Concentrations IgG concentration 0.1 mg/ml

Immunogen Synthetic peptide sequence corresponding to the C-terminal region (residues 408-439) of human c-myc conjugated to keyhole limpet hemocyanin.

**External Database
Links**

UniProt:

[P01106](#) [Related reagents](#)

Entrez Gene:

[4609](#) MYC [Related reagents](#)

Synonyms

BHLHE39

Fusion Partners

Spleen cells from immunised BALB/c mice were fused with cells of the SP2/0 myeloma cell line.

Specificity

Mouse anti c-myc antibody, clone 9E10 detects the p62^{c-myc} proto-oncogene protein, which is involved in the regulation of the cell cycle and cell growth. C-myc is primarily located to the cell nucleus, but has also been shown to localised to the cytoplasm in several cell lines ([Craig *et al.* 1993](#)). Overexpression of c-myc has been reported in a wide variety of human cancers ([Nesbit *et al.* 1999](#)).

Mouse anti c-myc antibody, clone 9E10 recognizes the sequence EQKLISEEDL and may be used to detect proteins and peptides labelled with molecular tags containing this sequence ([Hilpert *et al.* 2001](#)).

Flow Cytometry

Use 10ul of the suggested working dilution to label 1x10⁶ cells in 100ul.

Immunohistology

This product does not require protein digestion pre-treatment of paraffin sections prior to staining
This product does not require antigen retrieval using heat treatment prior to staining of paraffin sections.

References

1. Evan, G.I. *et al.* (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. [Mol Cell Biol. 5 \(12\): 3610-6.](#)
2. Spandidos, D.A. *et al.* (1987) Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. [Anticancer Res. 7 \(6\): 1299-304.](#)
3. Borodina, I. *et al.* (2010) Display of wasp venom allergens on the cell surface of *Saccharomyces cerevisiae*. [Microb Cell Fact. 9: 74.](#)
4. Groeger, G. *et al.* (2007) Co-operative Cdc42 and Rho signalling mediates ephrinB-triggered endothelial cell retraction. [Biochem J. 404: 23-9.](#)
5. Head, B. *et al.* (2009) Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. [J Cell Biol. 187: 959-66.](#)
6. Hilpert, K. *et al.* (2001) Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. [Protein Eng. 14: 803-6.](#)
7. Krauss, N. *et al.* (2008) The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops. [Proteins. 73: 552-65.](#)
8. Gray, P. *et al.* (2010) Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling. [J Immunol. 184: 6359-66.](#)
9. Duriseti, S. *et al.* (2010) Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. [J Biol Chem. 285: 26878-88.](#)
10. Tan, P.H. *et al.* (2005) Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. [Blood. 106: 2936-43.](#)
11. Wallace, S.W. *et al.* (2010) Cdc42 regulates apical junction formation in human bronchial epithelial cells through PAK4 and Par6B. [Mol Biol Cell. 21: 2996-3006.](#)
12. Rowshanravan, B. *et al.* (2014) RasGAP mediates neuronal survival in *Drosophila* through direct regulation of Rab5-dependent endocytosis. [J Cell Sci. 127: 2849-61.](#)

13. Taylor K *et al.* (2015) Nanocell targeting using engineered bispecific antibodies. [MAbs. 7 \(1\): 53-65.](#)
14. Elders, R.C. *et al.* (2014) Recombinant canine IgE Fc and an IgE Fc-TRAIL fusion protein bind to neoplastic canine mast cells. [Vet Immunol Immunopathol. 159 \(1-2\): 29-40.](#)
15. Sharkey, A.M. *et al.* (2015) Tissue-Specific Education of Decidual NK Cells. [J Immunol. 195 \(7\): 3026-32.](#)
16. McGough, I.J. *et al.* (2014) Identification of molecular heterogeneity in SNX27-retromer-mediated endosome-to-plasma-membrane recycling. [J Cell Sci. 127 \(Pt 22\): 4940-53.](#)
17. Gohlke, S. *et al.* (2017) *In Vitro* and *In Vivo* Studies on the Structural Organization of Chs3 from *Saccharomyces cerevisiae*. [Int J Mol Sci. 18 \(4\): pii: E702.](#)

Further Reading 1. Nesbit, C. *et al.* (1999) MYC oncogenes and human neoplastic disease. [Oncogene. 18: 3004-16.](#)

Storage Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee 18 months from date of despatch.

Health And Safety Information Material Safety Datasheet documentation #10041 available at: 10041: <https://www.bio-rad-antibodies.com/uploads/MSDS/10041.pdf>

Regulatory For research purposes only

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

'M336627:181214'

Printed on 20 May 2019

© 2019 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)